Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three ...

Both drugs are JAK 1/2 inhibitors and have been cleared for use in adults with severe hair loss caused by the condition. Incyte filed a lawsuit to try to block the launch of Leqselvi, claiming ...

Sun Pharmaceutical has agreed to acquire Checkpoint Therapeutics for an aggregate consideration of up to $355m upfront.

Both drugs are already approved in the US ... sought by Incyte on the launch of Sun Pharma's recently approved Leqselvi for alopecia areata.

Mumbai: Sun Pharma's much anticipated US commercial launch of its specialty product Leqselvi (deuruxolitinib) is facing uncertainty due to a patent dispute. Leqselvi is used for the treatment of ...

However, on Friday, the court upheld the delay, effectively blocking Leqselvi’s entry into the U.S. market. In response, Sun Pharma stated in an exchange filing on Saturday, “We respectfully ...

Leqselvi is now FDA approved for treating severe alopecia areata. Sun Pharma added the oral drug to its pipeline via the $576 million acquisition of Concert Pharmaceuticals last year. Sun ...

Of the states that do provide coverage for JAK inhibitors used to treat patients with alopecia, researchers found that prior ...

These include slower-than-expected sales pick-up for key specialty brands, further delays in the launch of Leqselvi ... inhibitor drugs, which compete with Sun’s Ilumya brand, reported strong ...

The acquisition is set to add Checkpoint's US Food and Drug Administration (FDA)-approved ... Sun Pharma received FDA approval in July l2024 for Leqselvi (deuruxolitinib), an oral treatment ...